PIRFENIDONE THERAPY AND INDUCER OF CYTOCHROME P450

Japanese Patent JP2012153734

A

To provide methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.

The invention generally relates to improved methods for administering pirfenidone to a patient in need of pirfenidone therapy, and to methods for preparing or packaging pirfenidone medicaments, containers, packages and kits. In any of the aspects or embodiments, the patient can have idiopathic pulmonary fibrosis (IPF) and the medicament is for treatment of IPF.

JP4709489	Use of hydroxypyridone derivatives for wound healing
JP2023161073	MODIFIED NUCLEOBASES WITH UNIFORM HYDROGEN-BONDING INTERACTIONS, HOMO- AND HETERO-BASEPAIR BIAS, AND MISMATCH DISCRIMINATION
JP2019535822	Pharmaceutical use of sustained-release composition containing pirfenidone for the treatment and recovery of human steatohepatitis (NAFLD / NASH)

BRADFORD WILLIAMSON ZIEGLER
SZWARCBERG JAVIER

JP2012116700A

August 16, 2012

May 22, 2012

Click for automatic bibliography generation  

INTERMUNE INC

A61K31/4412; A61K45/00; A61P43/00; A61P1/16; A61P1/18; A61P9/00; A61P9/06; A61P9/10; A61P11/00; A61P11/02; A61P13/08; A61P13/12; A61P17/00; A61P19/02; A61P19/06; A61P19/10; A61P21/00; A61P21/04; A61P25/00; A61P25/14; A61P25/28; A61P29/00; A61P31/04; A61P31/12; A61P31/16; A61P31/18; A61P33/02; A61P33/06; A61P35/00; A61P37/00; A61P37/06; A61P37/08; A61P41/00; C07D213/64

JPN6012009507; 岡田賢二　他: 薬局 Ｖｏｌ．５４，　Ｎｏ．１１, 2003, ｐｐ．２７５７-２７６６
JPN7012000677; Ａｚｕｍａ，　Ａ．　ｅｔ　ａｌ．: Ａｍ．　Ｊ．　Ｒｅｓｐｉｒ．　Ｃｒｉｔ．　Ｃａｒｅ　Ｍｅｄ． Ｖｏｌ．１７１, 2005, ｐｐ．１０４０-１０４７
JPN6012009503; 嶋村京子: ちば県薬誌 Ｖｏｌ．５５，　Ｎｏ．６, 200905, ｐｐ．２３-２７
JPN6012009505; 千堂年昭　他: 薬局 Ｖｏｌ．５０，　Ｎｏ．１０, 1999, ｐｐ．８６-９０
JPN6012009506; 山田哲夫: 調剤と情報 Ｖｏｌ．１０，　Ｎｏ．１１, 2004, ｐｐ．１０５-１１０

Hidesaku Yamamoto
Takaaki Yasumura
Natsuki Morishita

Previous Patent: アクリル樹脂組成物、アクリル樹脂シート、アクリル樹脂積層体、及びそ�...

Next Patent: BIOSTATIC POLYMER